Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Tumor Infiltrating Lymphocytes for the Treatment of Children with High Risk Solid Tumors

Trial Status: active

This phase I trial tests the safety, side effects, feasibility and effectiveness of collecting, producing and giving tumor infiltrating lymphocytes (TIL) with lymphodepleting chemotherapy, with fludarabine and cyclophosphamide, and post infusion IL-2 for the treatment of children with high risk solid tumors. TIL are a form of small while blood cells. Some of these lymphocytes are good at fighting tumors and can go into them to attack the cancer cells. The cells are collected from the patients tumor tissue, grown in a lab and then returned to the body to attack tumor cells. Chemotherapy, with fludarabine and cytarabine, is given prior to the TIL treatment to help kill any remaining tumor cells and prepare the body to accept the TILs. IL-2 is given after to help the lymphocytes grow in the body. Giving TIL with lymphodepleting chemotherapy and post infusion IL-2 may be safe, feasible and/or effective in treating children with high risk solid tumors.